Life science companies have always been challenged to effectively develop, launch, and market new products in a competitive and fast-moving industry. Driving these decisions are expert insight from physicians, patients, payers, and internal stakeholders. But what if teams aren't talking to the right experts, or are engaging them ineffectively? And what happens if those insights aren't quickly used to inform strategy? This problem is known as the insight gap – a costly and risky problem that wastes time and money. In this paper, learn how to identify where the insight gap occurs, what causes it, and how to solve it.
Prior to 2020, many clinical teams approached virtual engagement with an experimental mindset. But when COVID-19 derailed trials and changed how global teams worked together, clinical groups quickly learned the benefits of combining asynchronous virtual engagement with live touchpoints. In this white paper, clinical team leads will learn how their peers are using hybrid virtual engagement to get more actionable insights, prioritize patient-centricity, gather more diverse perspectives, and overcome budget limitations.
Want to learn how your industry peers are getting more work done while having fewer meetings? The answer lies in adopting the concept of virtual work instead of relying on video calls alone. In this white paper, learn the differences between virtual work and virtual meetings, what it means for pharmaceutical and medical device teams, and real-world examples of virtual work in action.
Medical device teams weren't immune to sweeping changes in 2020. Here are the top trends that will shape how medtech teams use virtual engagement to navigate the year ahead, including our recommendations for building competitive advantage.
Within3’s Virtual Engagement Partner program gives agencies the opportunity to have a virtual engagement solution at their fingertips to offer clients in brand planning. In this white paper, we draw on years of experience to pass along four best practices agencies can use in helping life science clients convert live meetings and events to successful virtual engagements.
The pharmaceutical industry is energizing its approach to patient engagement, adopting a patient-centric philosophy that prioritizes involving patients in a meaningful way throughout the drug development lifecycle. Both patients and pharmaceutical teams can benefit from over-time, asynchronous communication. We've compiled some of our best practices around these types of meetings to help medical affairs, clinical/R&D, and commercial teams get high-quality insights in a virtual engagement setting.
The events of early 2020 changed how life sciences companies do business almost overnight, forcing teams to convert live events to virtual meetings. But standing up a reliable way to meet with stakeholders online isn't just a stopgap – it's an investment for the future. Learn four best practices that will enable your team to make a successful switch to virtual meetings.
In some regions of the world, long distances and multiple languages make live, in-person meetings particularly costly and inefficient. With APAC spending on business travel expected to reach $900 billion by 2025, global pharmaceutical companies are increasingly turning to virtual engagement to reduce spending and environmental impact.
Webcasts and webinars can be powerful tools for HCP engagement, particularly when paired with asynchronous online discussion sessions. This paper outlines effective use of real-time web meetings when paired with "over-time" sessions.